Gennex Laboratories Share Price | Gennex Laboratories Stock Screener
GENNEX
Pharmaceuticals
Share Price BSE
₹10.95
▲
0.00 (0.00%)
As of May 20, 2026, the Gennex Laboratories share price (BSE: GENNEX) is ₹10.95, unchanged from the previous close, with shares trading between ₹10.61 and ₹11.40, and a 52-week range of ₹7.13–₹17.02.
Check GENNEX yearly price range for the annual price range and momentum.
Use the Gennex Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Gennex Laboratories Market Cap
₹231.24 Cr.
GENNEX P/E Ratio (TTM)
11.74
Gennex Laboratories P/B Ratio
1.08
EPS (TTM)
₹0.80
Dividend Yield
-
Debt to Equity
0.04
GENNEX 52 Week High
₹17.02
Gennex Laboratories 52 Week Low
₹7.13
Operating Margin
14.00%
Profit Margin
15.00%
GENNEX Revenue (TTM)
₹40.00
EBITDA
₹6.00
Net Income
₹6.00
Total Assets
₹256.00
Total Equity
₹195.00
Gennex Laboratories Share Price Chart
Screen Gennex Laboratories share price with an interactive chart. Analyse GENNEX price trends and volatility across different timeframes.
Gennex Laboratories Company Profile - Fundamental Screener
Screen Gennex Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for GENNEX shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE509C01026
Gennex Laboratories Balance Sheet Screener
Screen GENNEX balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total Assets | 256 | 230 | 132 | 68 | 59 | 57 | 52 | 51 | 49 |
| Current Assets | 181 | 162 | 49 | 47 | 38 | 35 | 29 | 28 | 26 |
| Fixed Assets | 60 | 56 | 74 | 14 | 14 | 15 | 16 | 16 | 16 |
| Liabilities | |||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 17 | 13 | 16 | 0 | 0 | 0 | 1 | 1 | 1 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | |||||||||
| Total Equity | 195 | 177 | 87 | 44 | 40 | 36 | 34 | 32 | 31 |
| Share Capital | 23 | 23 | 18 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves & Surplus | 158 | 142 | 62 | 31 | 27 | 23 | 21 | 19 | 18 |
Gennex Laboratories Income Statement Screener - Profit & Revenue Analysis
Screen Gennex Laboratories income statement and profit fundamentals.
Analyze GENNEX quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Gennex Laboratories share price evaluation.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40 | 37 | 37 | 44 | 38 | 32 | 31 | 34 | 19 | 18 | 17 | 19 | 14 | 19 | 14 |
| Expenses | 35 | 32 | 29 | 39 | 33 | 26 | 24 | 29 | 17 | 12 | 11 | 17 | 13 | 18 | 13 |
| EBITDA | 6 | 6 | 7 | 6 | 5 | 6 | 7 | 4 | 3 | 5 | 5 | 1 | 1 | 1 | 1 |
| Operating Profit % | 14.00% | 15.00% | 15.00% | 5.00% | 13.00% | 18.00% | 15.00% | 13.00% | 13.00% | 29.00% | 31.00% | 7.00% | 8.00% | 7.00% | 6.00% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Profit Before Tax | 7 | 6 | 6 | 4 | 6 | 6 | 6 | 5 | 4 | 4 | 4 | 3 | 2 | 1 | 1 |
| Tax | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Net Profit | 6 | 6 | 5 | 3 | 5 | 5 | 5 | 5 | 3 | 3 | 3 | 2 | 1 | 1 | 1 |
| EPS | 0.22 | 0.21 | 0.22 | 0.14 | 0.22 | 0.21 | 0.19 | 0.16 | 0.16 | 0.16 | 0.16 | 0.19 | 0.07 | 0.08 | 0.06 |
Gennex Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen GENNEX cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -11 | -47 | 24 | 12 | -1 | -2 | 2 | 3 | 0 |
| Investing Activities | 1 | 19 | -38 | -3 | 0 | 0 | -1 | -1 | -1 |
| Financing Activities | 5 | 74 | 21 | -2 | 2 | 0 | 1 | -2 | 1 |
| Net Cash Flow | -5 | 46 | 6 | 8 | 0 | -2 | 2 | 0 | 0 |
Gennex Laboratories Shareholding Pattern Screener
See Gennex Laboratories shareholding pattern with promoter, FII, and DII holdings.
Check Gennex Laboratories promoter holding and ownership changes for GENNEX on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Jul | 2025-Sept | 2025-Dec | 2024-Feb | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 23.63% | 18.42% | 19.83% | 23.62% | 23.62% | 23.62% | 18.42% | 18.42% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 55.79% | 62.19% | 61.90% | 58.97% | 59.34% | 56.47% | 58.81% | 60.42% |
| Other Holding | 20.58% | 19.39% | 18.28% | 17.41% | 17.04% | 19.91% | 22.78% | 21.16% |
| Shareholder Count | 84,133 | 92,326 | 91,183 | 91,183 | 90,320 | 86,306 | 69,750 | 83,996 |
Gennex Laboratories Share Dividend Screener - Share Yield Analysis
Check Gennex Laboratories dividend history with payout and yield data.
View Gennex Laboratories dividend details including ex-dates and amounts for GENNEX stock.
Gennex Laboratories Stock Index Membership
See which indices include Gennex Laboratories stock.
Check GENNEX index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Gennex Laboratories Market Events Screener - Corporate Actions
Get Gennex Laboratories corporate actions including splits, bonuses, and buybacks.
Check Gennex Laboratories stock events that may affect GENNEX share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 27.26% | ||
| Annual General Meeting | NA | -0.44% | ||
| 2026-05-12 | 2026-05-12 | Extraordinary General Meeting | NA | -2.64% |
| 2026-02-14 | 2026-02-14 | Quarterly Result Announcement | NA | -1.68% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | 1.36% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | -4.23% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | 5.19% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | -6.70% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -5.88% |
| 2023-12-30 | 2023-12-30 | Extraordinary General Meeting | NA | 4.41% |
| 2022-07-21 | 2022-07-22 | Rights | 1:2 | 2.40% |
Gennex Laboratories Competitors Screener - Peer Comparison
Screen GENNEX competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 450,643 | 40.81 | 54,729 | 9.71% | 10,980 | 64.89 |
| Divis Laboratories | 179,470 | 74.13 | 9,712 | 18.67% | 2,191 | 64.06 |
| Torrent Pharmaceuticals | 149,109 | 65.68 | 11,539 | 6.99% | 1,911 | 58.52 |
| Cipla | 115,682 | 30.09 | 27,712 | -2.46% | 3,783 | 69.78 |
| Dr Reddys Laboratories | 111,567 | 26.16 | 33,593 | -0.44% | 3,998 | 59.87 |
| Lupin | 104,032 | 19.28 | 27,488 | 19.98% | 5,345 | 46.11 |
| Mankind Pharma | 103,325 | 56.36 | 12,744 | 20.90% | 2,007 | 73.37 |
| Zydus Life Science | 101,801 | 19.85 | 23,511 | 18.55% | 4,615 | 69.47 |
| Aurobindo Pharma | 87,806 | 25.16 | 32,346 | 9.43% | 3,484 | 73.83 |
| Laurus Labs | 71,455 | 79.78 | 6,813 | 21.03% | 884 | 80.26 |
Gennex Laboratories Company Announcements - News Screener
Screen GENNEX latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-05-18 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | - |
| 2026-05-17 | Shareholder Meeting / Postal Ballot-Outcome of EGM | - |
| 2026-04-21 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-04-20 | Notice Convening Extraordinary General Meeting (EGM) To Be Held On Tuesday May 12 2026 Through VC And OAVM | - |
| 2026-04-17 | Board Meeting Outcome for Revised Outcome | - |
| 2026-04-16 | Board Meeting Outcome for For Meeting Held On April 16 2026 Of Gennex Laboratories Limited To Conduct EGM | - |
| 2026-04-13 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-04-08 | Board Meeting Intimation for Meeting To Be Held On Thursday April 16 2026 | - |
| 2026-03-25 | Closure of Trading Window | - |
| 2026-02-17 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-14 | Intimation Of Reconstitution Of Audit Committee Stakeholders Relationship Committee And Nomination And Remuneration Committee Under Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirement) Regulations 2015 | - |
| 2026-02-14 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-02-14 | Announcement under Regulation 30 (LODR)-Resignation of Director | - |
| 2026-02-14 | Quarter And Nine Months Ended December 31 2025 | - |
| 2026-02-14 | Board Meeting Outcome for Board Meeting Outcome For Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025 | - |
| 2026-02-09 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-05 | Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Nine Months Ended December 31 2025 | - |
| 2026-01-12 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-12-16 | Closure of Trading Window | - |
| 2025-11-17 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |